published meta-analysis   sensitivity analysis   studies

potential COVID-19 treatments in COVID 19 hospitalized - Summary of results

OutcomeTE95% CInkI2ROBPub. bias death D28detailed resultsFACCT Trial, 2021 0.69 [0.28; 1.68] HYDRA (Hernandez-Cardenas), 2021 0.80 [0.52; 1.24] RECOVERY, 2020 1.09 [0.97; 1.23] SOLIDARITY (WHO study) HCQ, 2020 1.19 [0.89; 1.59] 1.07[0.95; 1.21]FACCT Trial, 2021, HYDRA (Hernandez-Cardenas), 2021, RECOVERY, 2020, SOLIDARITY (WHO study) HCQ, 202046%7,037moderatenot evaluable deathsdetailed resultsAbd-Elsalam, 2020 1.21 [0.36; 4.12] Chen, 2020 0.56 [0.01; 30.20] Coalition Covid-19 Brazil I (Cavalcanti)-Hydroxychloroquine, 2020 1.09 [0.31; 3.84] FACCT Trial, 2021 0.96 [0.44; 2.08] Galan, 2021 0.94 [0.51; 1.73] Gonzalez (HCQ), 2020 0.33 [0.06; 1.78] HAHPS, 2020 7.00 [0.80; 60.90] HYCOVID, 2020 0.54 [0.21; 1.40] HYDRA (Hernandez-Cardenas), 2021 0.80 [0.52; 1.24] NO COVID-19 (Lyngbakken), 2020 0.96 [0.06; 15.78] NOR-Solidarity (hydroxychloroquine), 2021 3.10 [0.29; 33.20] ORCHID, 2020 1.07 [0.54; 2.11] RECOVERY, 2020 1.09 [0.97; 1.23] SOLIDARITY (WHO study) HCQ, 2020 1.19 [0.89; 1.59] TEACH, 2020 1.07 [0.34; 3.37] 1.07[0.97; 1.18]Abd-Elsalam, 2020, Chen, 2020, Coalition Covid-19 Brazil I (Cavalcanti)-Hydroxychloroquine, 2020, FACCT Trial, 2021, Galan, 2021, Gonzalez (HCQ), 2020, HAHPS, 2020, HYCOVID, 2020, HYDRA (Hernandez-Cardenas), 2021, NO COVID-19 (Lyngbakken), 2020, NOR-Solidarity (hydroxychloroquine), 2021, ORCHID, 2020, RECOVERY, 2020, SOLIDARITY (WHO study) HCQ, 2020, TEACH, 2020150%8,938moderatelow deaths (time to event analysis only)detailed resultsGalan, 2021 0.94 [0.51; 1.73] HYDRA (Hernandez-Cardenas), 2021 0.80 [0.52; 1.24] NOR-Solidarity (hydroxychloroquine), 2021 3.10 [0.29; 33.20] RECOVERY, 2020 1.09 [0.97; 1.23] SOLIDARITY (WHO study) HCQ, 2020 1.19 [0.89; 1.59] 1.08[0.97; 1.20]Galan, 2021, HYDRA (Hernandez-Cardenas), 2021, NOR-Solidarity (hydroxychloroquine), 2021, RECOVERY, 2020, SOLIDARITY (WHO study) HCQ, 202050%7,063moderatenot evaluable clinical deteriorationdetailed resultsCoalition Covid-19 Brazil I (Cavalcanti)-Hydroxychloroquine, 2020 1.21 [0.69; 2.12] HAHPS, 2020 1.07 [0.63; 1.82] TEACH, 2020 1.80 [0.62; 5.21] 1.20[0.83; 1.72]Coalition Covid-19 Brazil I (Cavalcanti)-Hydroxychloroquine, 2020, HAHPS, 2020, TEACH, 202030%460moderatenot evaluable clinical improvementdetailed resultsHuang, 2020 1.37 [0.73; 2.56] ORCHID, 2020 1.02 [0.73; 1.42] 1.09[0.81; 1.46]Huang, 2020, ORCHID, 202020%501lownot evaluable clinical improvement (14-day)detailed resultsChen, 2020 0.56 [0.13; 2.48] Coalition Covid-19 Brazil I (Cavalcanti)-Hydroxychloroquine, 2020 0.83 [0.47; 1.44] Huang, 2020 1.37 [0.73; 2.56] ORCHID, 2020 1.02 [0.73; 1.42] 1.01[0.78; 1.30]Chen, 2020, Coalition Covid-19 Brazil I (Cavalcanti)-Hydroxychloroquine, 2020, Huang, 2020, ORCHID, 202040%982lownot evaluable clinical improvement (28-day)detailed resultsORCHID, 2020 0.97 [0.69; 1.37] 0.97[0.69; 1.37]ORCHID, 202010%479NAnot evaluable clinical improvement (7-day)detailed resultsORCHID, 2020 1.16 [0.84; 1.61] 1.16[0.84; 1.61]ORCHID, 202010%479NAnot evaluable clinical improvement (time to event analysis only)detailed resultsFACCT Trial, 2021 0.85 [0.62; 1.16] HYDRA (Hernandez-Cardenas), 2021 1.05 [0.74; 1.48] ORCHID, 2020 0.97 [0.69; 1.36] 0.94[0.78; 1.14]FACCT Trial, 2021, HYDRA (Hernandez-Cardenas), 2021, ORCHID, 202030%947moderatenot evaluable death or ventilationdetailed resultsGonzalez (HCQ), 2020 0.69 [0.22; 2.21] HYCOVID, 2020 1.12 [0.45; 2.79] ORCHID, 2020 1.13 [0.60; 2.13] RECOVERY, 2020 1.14 [1.03; 1.27] SOLIDARITY (WHO study) HCQ, 2020 1.11 [0.87; 1.42] 1.13[1.03; 1.24]Gonzalez (HCQ), 2020, HYCOVID, 2020, ORCHID, 2020, RECOVERY, 2020, SOLIDARITY (WHO study) HCQ, 202050%6,570moderatenot evaluable hospital dischargedetailed resultsFACCT Trial, 2021 0.88 [0.64; 1.21] Gonzalez (HCQ), 2020 1.38 [0.46; 4.16] HAHPS, 2020 0.91 [0.54; 1.54] Huang, 2020 2.00 [1.15; 3.47] HYDRA (Hernandez-Cardenas), 2021 1.01 [0.72; 1.42] 1.09[0.82; 1.44]FACCT Trial, 2021, Gonzalez (HCQ), 2020, HAHPS, 2020, Huang, 2020, HYDRA (Hernandez-Cardenas), 2021543%645moderatenot evaluable mechanical ventilationdetailed resultsGalan, 2021 0.14 [0.03; 0.71] 0.14[0.03; 0.71]Galan, 202110%168NAnot evaluable radiologic improvement (14-day)detailed resultsHuang, 2020 1.33 [0.94; 1.88] 1.33[0.94; 1.88]Huang, 202010%22NAnot evaluable radiologic improvement (7-day)detailed resultsHuang, 2020 2.40 [0.26; 22.51] 2.40[0.26; 22.51]Huang, 202010%22NAnot evaluable viral clearance detailed resultsHuang, 2020 1.20 [0.78; 1.85] 1.20[0.78; 1.85]Huang, 202010%22NAnot evaluable viral clearance by day 14detailed resultsChen, 2020 1.42 [0.26; 7.76] Huang, 2020 1.09 [0.95; 1.26] 1.09[0.95; 1.26]Chen, 2020, Huang, 202020%55moderatenot evaluable viral clearance by day 7detailed resultsHuang, 2020 1.20 [0.60; 2.40] 1.20[0.60; 2.40]Huang, 202010%22NAnot evaluable ICU admissiondetailed resultsAbd-Elsalam, 2020 0.83 [0.35; 1.95] FACCT Trial, 2021 1.42 [0.79; 2.55] Galan, 2021 1.42 [0.68; 2.99] 1.26[0.84; 1.89]Abd-Elsalam, 2020, FACCT Trial, 2021, Galan, 202130%616moderatenot evaluable off oxygenationdetailed resultsHYDRA (Hernandez-Cardenas), 2021 0.98 [0.64; 1.51] 0.98[0.64; 1.51]HYDRA (Hernandez-Cardenas), 202110%214NAnot evaluable cardiac arrestdetailed resultsSOLIDARITY (WHO study) HCQ, 2020 1.92 [0.35; 10.49] 1.92[0.35; 10.49]SOLIDARITY (WHO study) HCQ, 202010%1,853NAnot evaluable serious adverse eventsdetailed resultsORCHID, 2020 1.26 [0.56; 2.84] 1.26[0.56; 2.84]ORCHID, 202010%479NAnot evaluable adverse eventsdetailed resultsCoalition Covid-19 Brazil I (Cavalcanti)-Hydroxychloroquine, 2020 0.88 [0.29; 2.65] Huang, 2020 1.80 [0.14; 23.37] ORCHID, 2020 1.42 [0.87; 2.34] RECOVERY, 2020 1.36 [0.98; 1.90] TEACH, 2020 1.16 [0.55; 2.42] 1.32[1.03; 1.70]Coalition Covid-19 Brazil I (Cavalcanti)-Hydroxychloroquine, 2020, Huang, 2020, ORCHID, 2020, RECOVERY, 2020, TEACH, 202050%5,677moderatenot evaluable0.05.01.0relative treatment effectwww.metaEvidence.org2024-04-28 12:30 +02:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 95,94,90,91 - treatments: 290,547,608,830,831,829,901,680,595,828,681,1209,833,629,689,543,617,625,859,511,960,546,564,944,682,1266,943,894,560,1102,598,563,668,753,752,836,639,541,534,581,615,679,522,582,666,1149,1150,737,544,733,597,524,611,538,957,958,521,566,517,881,904,882,897,896,899,1235,898,687,740,883,947,536,591,729,887,742,878,975,570,771,888,1141,690,880,1255,567,596,1437,600,652,557,635,1236,553,628,646,645,607,395,920,1438,927,932,931,1263,599,614,942,1436,928,923,535,1046,727,818,606,954,964,962,963,1045,638,677,627,533,526,616,926,1246,726,580,568,527,588,539,585,691,1210,525,843,827,1047,1048,819,545,1253,519,619,537,514,688,529,508,656,657,832,530,512,515,754,1142,1419,513,884,632,559,889,956,684,886,631,574,509,542,1145,555,554,941,961,1250,633,676,518,532,510,528,520,955,815,893,623,622,630,593,569,516,814,649,650,589,651,968,1245,610,751,747,695,548,970,594,565,879,1257,571,626,697,572,1234,586,573,540,592,930,949,838,698,934,735,929,948,946,945,587,655,1146,531,933,613,919,725,678,921,621,959,748,1348,1256,924,1243,925,658,699,612,552,590,891,605,892,722,618,609,551,834,763,922,935,620,1317,1265,824,766,857,1291,1088,1331,1330,1329,1344,1328,1327,979,822,762,805,950,757,761,806,758,826,755,821,1288,1287,1286,760,1284,802,765,1285,759,823,804,1264,764,858,835,1262,1290,1316,1341,1342,1343,825,803,1244,523,885,734,1439 - roots T: 290